#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Dementia Alzheimer's type Ovarian cancer Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Hereditary angioedema Philadelphia positive chronic myeloid leukaemia Infantile spasms Retinopathy of prematurity Hairy cell leukaemia Vernal keratoconjunctivitis Skin angiosarcoma Adrenocortical carcinoma Familial haemophagocytic lymphohistiocytosis Malignant central nervous system neoplasm Acute myeloid leukaemia refractory Thymic carcinoma Alpha-1 antitrypsin deficiency Oesophageal adenocarcinoma stage II Non-renal cell carcinoma of kidney More trials…

    Learn about Rare Diseases

    Activated PI3 kinase delta syndrome – Life with Disease Extranodal marginal zone B-cell lymphoma (MALT type) – Basic Information Osteosarcoma metastatic Propionic acidaemia – Life with Disease Chordoma – Diagnostics Familial haemophagocytic lymphohistiocytosis – Trials in Disease MELAS syndrome – Basic Information X-linked lymphoproliferative syndrome – Basic Information Anaplastic thyroid cancer – Treatment Encephalitis autoimmune – Trials in Disease More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Specific Nucleic Acid Sna-Her1 Sertindole Treosulfan Iptacopan Milademetan Ficlatuzumab Jnj-64042056 Metamizole Magnesium Daunorubicin Peboctocogene Camaparvovec Colecalciferol Farletuzumab Ecteribulin Capsaicin Serpina1(Human)-Aav8-1 Tiotropium Bromide Phenylephrine Grwd5769 Incb000928 Degarelix Acetate Ecoo1A More therapies…

    Learn about Your Condition

    Gaucher's disease type III Chronic hepatitis C Mesothelioma malignant Metastatic neoplasm Large cell lung cancer Dermatitis atopic Osteomyelitis acute Iron overload Aortic valve disease Hypoglycaemia Chronic coronary syndrome Peyronie's disease Tumour of ampulla of Vater CDKL5 deficiency disorder Vaginal cancer More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Neuroblastoma

  • Naxitamab Added to Standard Induction Therapy for Children and Teenagers with Newly Diagnosed High-Risk Neuroblastoma

    Recruiting

    2 1 1
    Investigated Diseases:
    • Neuroblastoma
    Investigated Drugs:
    • Naxitamab
    Spain

  • Indocyanine Green and Near-Infrared Fluorescence for Lymph Node Removal in Children with Renal Tumours or Paratesticular Rhabdomyosarcoma

    Recruiting

    2 1 1 1
    Investigated Drugs:
    • Indocyanine Green
    The Netherlands

  • Long-term safety study of GD2IL18CART treatment in patients with neuroblastoma, osteosarcoma, Ewing sarcoma, or advanced breast cancer

    Recruiting

    1 1 1
    Investigated Drugs:
    • Gd2Il18Cart
    Germany

  • Study of Temozolomide, Topotecan, Bevacizumab, Irinotecan and Dinutuximab Beta in Patients with High-Risk Relapsed Neuroblastoma

    Recruiting

    1 1 1 1
    Investigated Drugs:
    • Dinutuximab Beta
    • Topotecan
    • Bevacizumab
    Austria Belgium Denmark France Germany Italy +4

  • Study of GD2-CAR T Cells, Cyclophosphamide, and Fludarabine for Children with High-Risk or Relapsed Neuroblastoma and Other GD2+ Tumors

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • Neuroblastoma
    Investigated Drugs:
    • AUTOLOGOUS T CELLS TRANSDUCED WITH A RETROVIRAL VECTOR ENCODING A CHIMERIC ANTIGEN RECEPTOR AGAINST GD2, EX-VIVO EXPANDED
    • RIMIDUCID
    • Fludarabine Phosphate
    Italy

  • Study on Stem Cell Transplantation and Immunotherapy with Rituximab, Dinutuximab Beta, and Drug Combination for Patients with High-Risk Relapsed Neuroblastoma

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • Neuroblastoma
    Investigated Drugs:
    • ALLOGENEIC PERIPHERAL BLOOD-DERIVED HAEMATOPOIETIC STEM CELLS, TCR ALPHA/BETA+ CD19+ DEPLETED
    • ALLOGENEIC PERIPHERAL BLOOD-DERIVED NK CELLS CD3- CD56+
    • Dinutuximab Beta
    Italy
1 2 3 … 5
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!